GlaxoSmithKline would consider spinning off its consumer healthcare division. That's the view of the British drugmaker's CEO. In an interview with the Financial Times Sir Andrew Witty said the split wasn't planned for the near future, but GSK might pursue it if the division had more value as a standalone company.